ES2185338T3 - Derivados de fumagilol y procedimientos para su fabricacion. - Google Patents

Derivados de fumagilol y procedimientos para su fabricacion.

Info

Publication number
ES2185338T3
ES2185338T3 ES99919688T ES99919688T ES2185338T3 ES 2185338 T3 ES2185338 T3 ES 2185338T3 ES 99919688 T ES99919688 T ES 99919688T ES 99919688 T ES99919688 T ES 99919688T ES 2185338 T3 ES2185338 T3 ES 2185338T3
Authority
ES
Spain
Prior art keywords
substituted
fumagilol
halogen
unsubstituted
procedures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99919688T
Other languages
English (en)
Inventor
Chung Il Hong
Jung Woo Kim
Sang Joon Lee
Soon Kil Ahn
Nam Song Choi
Ryung Kee Hong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chong Kun Dang Corp
Original Assignee
Chong Kun Dang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Corp filed Critical Chong Kun Dang Corp
Application granted granted Critical
Publication of ES2185338T3 publication Critical patent/ES2185338T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/08—Compounds containing oxirane rings with hydrocarbon radicals, substituted by halogen atoms, nitro radicals or nitroso radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Derivado de fumagilol representado por la Fórmula Química 1 o una sal del mismo farmacéuticamente aceptable: en la que, X representa un grupo hidroxi e Y representa un halógeno, o X e Y pueden formar un anillo oxiránico; B representa oxígeno o hidrógeno; y R1, R2, R3, R4 y R5 independientemente representan hidrógeno, hidroxi, acetoxi, amino substituido o no substituido, alquilo substituido o no substituido, aminoalcoxi substituido o no substituido, C1-C6 alcoxi, halógeno, ciano, trifuorometilo, nitro, alquilendioxi, formilo, acetamido o metilenoxicarboxilo, con la condición de que R1, R2, R3, R4 y R5 no representen hidrógeno al mismo tiempo.
ES99919688T 1998-05-15 1999-05-11 Derivados de fumagilol y procedimientos para su fabricacion. Expired - Lifetime ES2185338T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR19980017636 1998-05-15

Publications (1)

Publication Number Publication Date
ES2185338T3 true ES2185338T3 (es) 2003-04-16

Family

ID=19537397

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99919688T Expired - Lifetime ES2185338T3 (es) 1998-05-15 1999-05-11 Derivados de fumagilol y procedimientos para su fabricacion.

Country Status (10)

Country Link
US (1) US6063812A (es)
EP (1) EP1077964B1 (es)
JP (1) JP3370985B2 (es)
KR (1) KR100357542B1 (es)
CN (1) CN100352810C (es)
AU (1) AU3734699A (es)
CA (1) CA2331873C (es)
DE (1) DE69903279T2 (es)
ES (1) ES2185338T3 (es)
WO (1) WO1999059986A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105482B2 (en) 2000-11-01 2006-09-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
AU2002239479B2 (en) 2000-11-01 2006-11-09 Praecis Pharmaceuticals Incorporated Peptides as Met-AP2 inhibitors
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
KR100455900B1 (ko) * 2001-09-27 2004-11-12 주식회사 아이디알 새로운 푸마질롤 유도체 및 그의 제조방법
KR100451485B1 (ko) * 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
KR100552043B1 (ko) * 2004-02-28 2006-02-20 주식회사종근당 푸마질롤 유도체를 포함하는 비만치료용 조성물
CA2594951A1 (en) * 2005-01-26 2006-08-03 Chong Kun Dang Pharmaceutical Corp. Fumagillol derivatives or method for preparation of fumagillol derivatives, and pharmaceutical compositions comprising the same
EP1967175A1 (en) * 2007-03-06 2008-09-10 Cognis IP Management GmbH Use of derivatives of sinapinic acid and compositions comprising such derivatives
MX2010005857A (es) * 2007-11-28 2010-11-22 Mersana Therapeutics Inc Conjugados de analogos de fumagillina biodegradables biocompatibles.
EP2317845A4 (en) 2008-07-18 2011-11-09 Zafgen Inc METHOD FOR TREATING AN OVERWEIGHT OR FATABLE PERSON
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
WO2010065883A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
JP5890312B2 (ja) 2009-10-09 2016-03-22 ザフゲン，インコーポレイテッド 肥満治療に用いられるスルホン化合物
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
MX343135B (es) 2010-01-08 2016-10-25 Zafgen Corp * Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
WO2011088055A2 (en) 2010-01-12 2011-07-21 Zafgen Corporation Methods and compositions for treating cardiovascular disorders
US20130266578A1 (en) 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
CN107141410B (zh) 2010-05-25 2022-12-09 辛德弗雷克斯公司 聚合物缀合的MetAP2抑制剂及其应用的治疗方法
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
EP2595988B1 (en) 2010-07-22 2014-12-17 Zafgen, Inc. Tricyclic compounds and methds of making and using same
CA2817199C (en) * 2010-11-09 2019-01-15 Zafgen, Inc. Crystalline solids of a metap-2 inhibitor and methods of making and using same
WO2012064928A1 (en) 2010-11-10 2012-05-18 Zafgen Corporation Methods and compositions for treating thyroid hormone related disorders
US20130316994A1 (en) 2010-11-29 2013-11-28 Zafgen, Inc. Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors
EP2646016B1 (en) 2010-11-29 2017-05-17 Zafgen, Inc. Treatment if obesity using non-daily administration of 6-0-(4-dimethylaminoethoxy)cinnamoyl fumagillol
US9189078B2 (en) 2010-12-20 2015-11-17 Apple Inc. Enhancing keycap legend visibility with optical components
JP6058557B2 (ja) 2011-01-26 2017-01-11 ザフゲン，インコーポレイテッド テトラゾール化合物ならびにその作製方法および使用方法
EP2683706B1 (en) 2011-03-08 2018-02-21 Zafgen, Inc. Oxaspiro [2.5]octane derivatives and analogs
CN103748094B (zh) 2011-05-06 2016-06-29 扎夫根股份有限公司 三环磺酰胺化合物及其制备和使用方法
KR101979039B1 (ko) 2011-05-06 2019-05-15 자프겐 인크. 부분 포화된 삼환식 화합물 및 그리고 그의 제조방법 및 그를 이용하는 방법
US9242997B2 (en) 2011-05-06 2016-01-26 Zafgen, Inc. Tricyclic pyrazole sulphonamide compunds and methods of making and using same
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
US9359369B2 (en) 2012-01-18 2016-06-07 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
CN104169268A (zh) 2012-01-18 2014-11-26 扎夫根股份有限公司 三环砜化合物及其制备和使用方法
WO2013169727A1 (en) 2012-05-07 2013-11-14 Zafgen, Inc. Polymorphic salt of the oxalate salt of 6 - o - ( 4 - dimethylaminoethoxy) cinnarnoyl fumagillol and methods of making and using same
JP2015516426A (ja) 2012-05-08 2015-06-11 ザフゲン，インコーポレイテッド ＭｅｔＡＰ２阻害剤による視床下部性肥満症の治療
US9573918B2 (en) 2012-05-09 2017-02-21 Zafgen, Inc. Fumigillol compounds and methods of making and using same
BR112015010225A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos e seus métodos de produção e utilização
BR112015010196A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc métodos de tratar doença do fígado
KR20150080614A (ko) 2012-11-05 2015-07-09 자프겐 인크. 비만의 치료 및/또는 제어에서 사용하기 위한 트리시클릭 화합물
WO2014152861A2 (en) 2013-03-14 2014-09-25 Zafgen, Inc. Methods of treating renal disease and other disorders
JP6420314B2 (ja) 2013-04-10 2018-11-07 シンデブルックス，インコーポレイティド Ｍｅｔａｐ２阻害剤及び肥満症の治療方法
TW201636342A (zh) * 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
US9969722B2 (en) 2015-12-10 2018-05-15 Syndevrx, Inc. Fumagillol derivatives and polymorphs thereof
AU2017206718B2 (en) 2016-01-11 2021-09-30 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
EP3870231A1 (en) 2018-10-26 2021-09-01 Syndevrx, Inc. Biomarkers of metap2 inhibitors and applications thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH26256A (en) * 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
CA1329771C (en) * 1988-09-01 1994-05-24 Shoji Kishimoto Angiogenesis inhibitory agent
ATE97410T1 (de) * 1989-03-06 1993-12-15 Takeda Chemical Industries Ltd 6-amino-6-desoxyfumagillole, ihre herstellung und ihre verwendung.
US5290807A (en) * 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
EP0415294A3 (en) * 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
ATE205092T1 (de) * 1992-01-30 2001-09-15 Takeda Chemical Industries Ltd Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative

Also Published As

Publication number Publication date
DE69903279T2 (de) 2003-08-07
KR100357542B1 (ko) 2002-10-18
JP3370985B2 (ja) 2003-01-27
DE69903279D1 (de) 2002-11-07
CN100352810C (zh) 2007-12-05
JP2002515497A (ja) 2002-05-28
WO1999059986A1 (en) 1999-11-25
CA2331873A1 (en) 1999-11-25
CN1301260A (zh) 2001-06-27
US6063812A (en) 2000-05-16
CA2331873C (en) 2005-12-06
EP1077964B1 (en) 2002-10-02
EP1077964A1 (en) 2001-02-28
AU3734699A (en) 1999-12-06
KR19990088113A (ko) 1999-12-27

Similar Documents

Publication Publication Date Title
ES2185338T3 (es) Derivados de fumagilol y procedimientos para su fabricacion.
NL350075I2 (es)
MX9302214A (es) Derivados de taxol y proceso para su preparacion
ES2188194T3 (es) 1,8-naftiridin-4(1h)-onas sustituidas como inhibidores de la fosfodiesterasa 4.
ATE283253T1 (de) Substituierte aminopropoxyarylderivate als lxr agonisten
ES2189502T3 (es) Metodo para la prevencion de citalopram.
CO5150159A1 (es) Derivados de 4-arilquinolin-2-ona 3-substituida como moduladores de los canales de potasio
YU69902A (sh) Novi derivati piperazina
DE69705829D1 (de) Meta-substituierte phenylsulphonamidderivate
DK0931788T3 (da) Metalloproteasehæmmere
TR200003036T2 (tr) 12,13-Modifiye edilmiş epotilon türevleri
PT923554E (pt) N-benzilpiperidina e derivados tetrahidropiridina
ECSP082712A (es) Procedimiento i para preparar derivados de tiazolidindiona
AR002711A1 (es) Un compuesto de 2-carboxindol-3-substituido,un proceso para su preparacion, un nuevo compuesto intermediario para dicho proceso, el uso del compuesto parala fabricacion de un agente terapeutico y una composicion farmaceutica que comprende dicho compuesto.
ES2191963T3 (es) Derivados triciclicos de triazolobenzazepina, proceso para la obtencion de los mismos y agentes antialergicos.
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
ES2191341T3 (es) Derivados de la 2-fenoxianilina.
ES2073258T3 (es) Nuevos derivados de la urea, su preparacion y su aplicacion en terapeutica.
MXPA02012569A (es) Ftalidas substituidas novedosas, un procedimiento para su preparacion y las composiciones farmaceuticas que contienen a las mismas.
MX9306529A (es) Derivados de pirazol condensado, metodo para fabricarlos y composicion farmaceutica que los contiene
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
PT1204658E (pt) Agonistas benzofurilpiperazina de serotonina
EA200000532A2 (ru) НОВЫЕ СОЕДИНЕНИЯ 7-ОКСО-2,3,7,14-ТЕТРАГИДРО-1H-БЕНЗО[b]-ПИРАНО [3,2-h]АКРИДИНКАРБОКСИЛАТА, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
CO5040081A1 (es) Nuevos compuestos vidad farmaaceutica
HRP980496B1 (en) New thilozine hydroxy derivatives and a process for the preparation thereof